A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Three Doses of AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia.
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Drinabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 18 Dec 2008 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
- 18 Dec 2008 Planned number of patients changed from 300 to 345 as reported by ClinicalTrials.gov.
- 18 Sep 2007 Status changed from in progress to completed.